Total Payments
$95,850
2024 Payments
$26,383
Companies
20
Transactions
99
Medicare Patients
938
Medicare Billing
$128,254
Payment Breakdown by Category
Consulting$45,215 (47.2%)
Other$31,135 (32.5%)
Travel$16,122 (16.8%)
Food & Beverage$2,405 (2.5%)
Research$949.58 (1.0%)
Education$23.29 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $45,215 | 25 | 47.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $31,135 | 6 | 32.5% |
| Travel and Lodging | $16,122 | 17 | 16.8% |
| Food and Beverage | $2,405 | 45 | 2.5% |
| Unspecified | $949.58 | 4 | 1.0% |
| Education | $23.29 | 2 | 0.0% |
Payments by Type
General
$94,900
95 transactions
Research
$949.58
4 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $47,601 | 15 | $0 (2024) |
| EISAI INC. | $9,691 | 16 | $0 (2022) |
| GlaxoSmithKline, LLC. | $9,093 | 8 | $0 (2023) |
| Seagen Inc. | $8,247 | 7 | $0 (2023) |
| Acrotech Biopharma Inc. | $6,055 | 7 | $0 (2024) |
| AbbVie Inc. | $5,681 | 10 | $0 (2020) |
| Clovis Oncology, Inc. | $5,247 | 10 | $0 (2022) |
| PFIZER INC. | $3,075 | 2 | $0 (2024) |
| TESARO, Inc. | $414.44 | 3 | $0 (2018) |
| ImmunoGen, Inc. | $270.57 | 4 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $26,383 | 18 | Merck Sharp & Dohme LLC ($16,925) |
| 2023 | $35,373 | 21 | Merck Sharp & Dohme LLC ($26,381) |
| 2022 | $3,677 | 5 | Merck Sharp & Dohme LLC ($2,440) |
| 2021 | $5,701 | 4 | Seagen Inc. ($3,850) |
| 2020 | $16,391 | 23 | Eisai Inc. ($6,064) |
| 2019 | $7,474 | 12 | EISAI INC. ($3,606) |
| 2018 | $459.57 | 5 | TESARO, Inc. ($393.37) |
| 2017 | $390.46 | 11 | Clovis Oncology, Inc. ($249.33) |
All Payment Transactions
99 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/25/2024 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Food and Beverage | In-kind items and services | $92.98 | General |
| Category: Oncology | ||||||
| 11/25/2024 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Food and Beverage | In-kind items and services | $28.33 | General |
| Category: Oncology | ||||||
| 11/12/2024 | Acrotech Biopharma Inc. | RYZNEUTA (Drug) | Consulting Fee | Cash or cash equivalent | $4,500.00 | General |
| Category: ONCOLOGY | ||||||
| 11/12/2024 | Acrotech Biopharma Inc. | RYZNEUTA (Drug) | Travel and Lodging | In-kind items and services | $38.74 | General |
| Category: ONCOLOGY | ||||||
| 11/12/2024 | Acrotech Biopharma Inc. | RYZNEUTA (Drug) | Food and Beverage | In-kind items and services | $17.52 | General |
| Category: ONCOLOGY | ||||||
| 11/07/2024 | Acrotech Biopharma Inc. | RYZNEUTA (Drug) | Travel and Lodging | In-kind items and services | $1,017.95 | General |
| Category: ONCOLOGY | ||||||
| 11/07/2024 | Acrotech Biopharma Inc. | RYZNEUTA (Drug) | Travel and Lodging | In-kind items and services | $192.66 | General |
| Category: ONCOLOGY | ||||||
| 11/07/2024 | Acrotech Biopharma Inc. | RYZNEUTA (Drug) | Food and Beverage | In-kind items and services | $162.84 | General |
| Category: ONCOLOGY | ||||||
| 11/07/2024 | Acrotech Biopharma Inc. | RYZNEUTA (Drug) | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: ONCOLOGY | ||||||
| 10/07/2024 | PFIZER INC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,500.00 | General |
| 07/16/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $20.42 | General |
| Category: Oncology | ||||||
| 07/10/2024 | Merck Sharp & Dohme LLC | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $7,320.00 | General |
| 07/01/2024 | PFIZER INC. | TIVDAK (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,575.00 | General |
| Category: Oncology | ||||||
| 05/21/2024 | INTUITIVE SURGICAL, INC. | Da Vinci Surgical System (Device) | Food and Beverage | In-kind items and services | $68.26 | General |
| Category: SURGERY | ||||||
| 04/03/2024 | Merck Sharp & Dohme LLC | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $7,320.00 | General |
| 04/03/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | Cash or cash equivalent | $150.00 | General |
| 01/29/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $2,135.00 | General |
| 01/16/2024 | ImmunoGen, Inc. | ELAHERE (Drug) | Food and Beverage | In-kind items and services | $118.65 | General |
| Category: ONCOLOGY | ||||||
| 12/21/2023 | GlaxoSmithKline, LLC. | JEMPERLI (Biological) | Consulting Fee | Cash or cash equivalent | $2,400.00 | General |
| Category: ONCOLOGY | ||||||
| 12/11/2023 | Merck Sharp & Dohme LLC | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $7,320.00 | General |
| 12/11/2023 | Merck Sharp & Dohme LLC | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,100.00 | General |
| 12/11/2023 | Merck Sharp & Dohme LLC | — | Travel and Lodging | Cash or cash equivalent | $150.00 | General |
| 12/11/2023 | Merck Sharp & Dohme LLC | — | Travel and Lodging | Cash or cash equivalent | $150.00 | General |
| 12/02/2023 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $82.64 | General |
| 12/01/2023 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $11,863.37 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Single Arm, Multicenter, International Trial of Tisotumab Vedotin HuMax-TF-ADC in Previously Treated, Recurrent or Metastatic Cervical Cancer | Seattle Genetics, Inc. | $42.75 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 176 | 263 | $73,617 | $22,776 |
| 2022 | 7 | 243 | 348 | $97,973 | $34,450 |
| 2021 | 8 | 310 | 474 | $127,172 | $45,970 |
| 2020 | 6 | 209 | 339 | $82,866 | $25,057 |
Total Patients
938
Total Services
1,424
Medicare Billing
$128,254
Procedure Codes
29
All Medicare Procedures & Services
29 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 42 | 111 | $38,739 | $11,528 | 29.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 47 | 57 | $14,022 | $3,865 | 27.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 19 | 23 | $5,629 | $2,380 | 42.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 29 | 30 | $3,438 | $1,733 | 50.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 14 | 14 | $7,126 | $1,725 | 24.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 14 | 17 | $2,737 | $789.60 | 28.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 11 | 11 | $1,926 | $756.40 | 39.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 47 | 114 | $38,805 | $14,116 | 36.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 99 | 119 | $24,282 | $9,075 | 37.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 30 | 30 | $14,538 | $4,945 | 34.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 17 | 22 | $7,678 | $2,487 | 32.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 15 | 15 | $5,283 | $1,602 | 30.3% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 12 | 24 | $5,040 | $1,330 | 26.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 11 | 11 | $1,723 | $538.71 | 31.3% |
| G0008 | Administration of influenza virus vaccine | Office | 2022 | 12 | 13 | $624.00 | $356.24 | 57.1% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 51 | 137 | $47,704 | $18,054 | 37.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 133 | 178 | $38,016 | $14,879 | 39.1% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 24 | 24 | $10,935 | $3,716 | 34.0% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 15 | 37 | $10,989 | $2,951 | 26.9% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 43 | 47 | $7,375 | $2,737 | 37.1% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 12 | 12 | $4,491 | $1,470 | 32.7% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 16 | 23 | $4,830 | $1,277 | 26.4% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2021 | 16 | 16 | $2,832 | $886.40 | 31.3% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 107 | 210 | $47,994 | $14,705 | 30.6% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 30 | 30 | $14,538 | $4,540 | 31.2% |
About Charles Leath
Charles Leath is a Gynecologic Oncology healthcare provider based in Birmingham, Alabama. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/16/2005. The National Provider Identifier (NPI) number assigned to this provider is 1255313193.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Charles Leath has received a total of $95,850 in payments from pharmaceutical and medical device companies, with $26,383 received in 2024. These payments were reported across 99 transactions from 20 companies. The most common payment nature is "Consulting Fee" ($45,215).
As a Medicare-enrolled provider, Leath has provided services to 938 Medicare beneficiaries, totaling 1,424 services with total Medicare billing of $128,254. Data is available for 4 years (2020–2023), covering 29 distinct procedure/service records.
Ad
Practice Information
- Specialty Gynecologic Oncology
- Location Birmingham, AL
- Active Since 11/16/2005
- Last Updated 02/01/2024
- Taxonomy Code 207VX0201X
- Entity Type Individual
- NPI Number 1255313193
Products in Payments
- Lenvima (Drug) $9,691
- JEMPERLI (Biological) $7,000
- RYZNEUTA (Drug) $6,055
- TIVDAK (Biological) $6,012
- Rubraca (Drug) $5,247
- ZEJULA (Drug) $307.28
- Elahere (Biological) $151.92
- XPOVIO (Drug) $121.31
- ELAHERE (Drug) $118.65
- Da Vinci Surgical System (Device) $101.37
- FOUNDATIONONE (Device) $57.37
- Fyarro (Drug) $50.17
- LYNPARZA (Drug) $32.05
- KEYTRUDA (Biological) $24.95
- SANCUSO (Drug) $22.38
- Upsylon (Device) $20.27
- SUBSYS (Drug) $14.64
- Endosee (Device) $12.54
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gynecologic Oncology Doctors in Birmingham
Dr. Rebecca Arend, M.d, M.D
Gynecologic Oncology — Payments: $110,102
Gynecologic Oncology $110,102
Warner Huh, Md, MD
Gynecologic Oncology — Payments: $88,407
Gynecologic Oncology $88,407
David Doo, Md, MD
Gynecologic Oncology — Payments: $17,328
Gynecologic Oncology $17,328
Dr. Wesley Burkett, M.d, M.D
Gynecologic Oncology — Payments: $1,998
Gynecologic Oncology $1,998
Jaclyn Wall, M.d, M.D
Gynecologic Oncology — Payments: $1,486
Gynecologic Oncology $1,486
Margaret Liang
Gynecologic Oncology — Payments: $1,340
Gynecologic Oncology $1,340